28A-1080820
2019-10-15
TW I717848、US 12,116,407 B2
Provided herein is a method for treating neurodegenerative diseases, such as Alzheimer's disease, by use of monoclonal antibody, which exhibits a binding affinity to Siglec receptor. According to some embodiments of the present disclosure, the monoclonal antibody is capable of enhancing phagocytosis of neurotoxic peptides by immune cells thereby providing a neuroprotective effect to a subject in need thereof.
- The sequences of the human anti-human Siglec mAbs are derived from human genome, thus reduces the risk of host immunity against anti-Siglec mAbs.
- These antibodies are able to downregulate Siglec expression and block alpha 2,6 sialoglycan and Siglec interactions.
- Therapeutic antibodies for the treatment and prevention of Alzheimer's disease.
- Therapeutic antibodies for the treatment and prevention of disease due to the accumulation of particulate antigens.
Shie-Liang Hsieh, An-Suei Yang, Pei-Shan Sung, Ming-Ting Huang, Chung-Ming Yu
If you are interested in this technology, please fill in the information on the webpage under the manufacturer option (Request for Technology Licensing, Material Transfer, or Sponsored Research) on the website of this office

Application of anti-Siglect mAb for the treatment Alzheimer disease